{"title":"阿司匹林对肝切除术后肝细胞癌患者预后的影响：倾向分数匹配分析。","authors":"Takashi Matsumoto, Yuki Kitano, Katsunori Imai, Daisuke Ogawa, Shinsei Yumoto, Toru Takematsu, Yuta Shiraishi, Rumi Itoyama, Shigeki Nakagawa, Kosuke Mima, Hirohisa Okabe, Hidetoshi Nitta, Hiromitsu Hayashi, Hideo Baba","doi":"10.1007/s10147-024-02646-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The association between aspirin and hepatocellular carcinoma (HCC) has been reported to prevent carcinogenesis caused by hepatitis B or C virus infection. The objective of this study was to investigate the prognostic impact of aspirin in patients who underwent liver resection for HCC.</p><p><strong>Methods: </strong>Data for 1032 patients who underwent primary resection for HCC between 2000 and 2019 were reviewed. There were 87 patients (8.4%) who took aspirin (aspirin group) and 945 (91.6%) who did not (non-aspirin group). Short-term outcomes, recurrence-free survival (RFS), and overall survival (OS) were compared between two groups in the matched cohort using propensity-score matching.</p><p><strong>Results: </strong>The median patient follow-up was 42.6 months (95% confidence interval 3.12-136.8 months). There was no significant difference in short-term outcomes, including bleeding events. RFS and OS after liver resection in the aspirin group were significantly better than those in the non-aspirin group in the unmatched cohort [5-year RFS rate: 50.3% vs 31.4%, hazard ratio (HR) 0.55, P = 0.0002; 5-year OS rate: 82.9% vs 70.2%, HR 0.46, P = 0.002]. In the matched cohort, RFS and OS after liver resection in the aspirin group were also significantly better than those in the non-aspirin group (5-year RFS rate: 50.3% vs 32.0%, HR 0.60, P = 0.003; 5-year OS rate: 82.9% vs 74.6%, HR 0.56, P = 0.03).</p><p><strong>Conclusion: </strong>Use of aspirin was associated with better prognosis for patients who underwent primary resection for HCC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic impact of aspirin in patients with hepatocellular carcinoma after liver resection: propensity-score-matched analysis.\",\"authors\":\"Takashi Matsumoto, Yuki Kitano, Katsunori Imai, Daisuke Ogawa, Shinsei Yumoto, Toru Takematsu, Yuta Shiraishi, Rumi Itoyama, Shigeki Nakagawa, Kosuke Mima, Hirohisa Okabe, Hidetoshi Nitta, Hiromitsu Hayashi, Hideo Baba\",\"doi\":\"10.1007/s10147-024-02646-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The association between aspirin and hepatocellular carcinoma (HCC) has been reported to prevent carcinogenesis caused by hepatitis B or C virus infection. The objective of this study was to investigate the prognostic impact of aspirin in patients who underwent liver resection for HCC.</p><p><strong>Methods: </strong>Data for 1032 patients who underwent primary resection for HCC between 2000 and 2019 were reviewed. There were 87 patients (8.4%) who took aspirin (aspirin group) and 945 (91.6%) who did not (non-aspirin group). Short-term outcomes, recurrence-free survival (RFS), and overall survival (OS) were compared between two groups in the matched cohort using propensity-score matching.</p><p><strong>Results: </strong>The median patient follow-up was 42.6 months (95% confidence interval 3.12-136.8 months). There was no significant difference in short-term outcomes, including bleeding events. RFS and OS after liver resection in the aspirin group were significantly better than those in the non-aspirin group in the unmatched cohort [5-year RFS rate: 50.3% vs 31.4%, hazard ratio (HR) 0.55, P = 0.0002; 5-year OS rate: 82.9% vs 70.2%, HR 0.46, P = 0.002]. In the matched cohort, RFS and OS after liver resection in the aspirin group were also significantly better than those in the non-aspirin group (5-year RFS rate: 50.3% vs 32.0%, HR 0.60, P = 0.003; 5-year OS rate: 82.9% vs 74.6%, HR 0.56, P = 0.03).</p><p><strong>Conclusion: </strong>Use of aspirin was associated with better prognosis for patients who underwent primary resection for HCC.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-024-02646-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02646-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：据报道，阿司匹林与肝细胞癌（HCC）之间存在关联，可预防由乙型或丙型肝炎病毒感染引起的癌变。本研究旨在探讨阿司匹林对因 HCC 而接受肝切除术的患者的预后影响：研究回顾了 2000 年至 2019 年期间因 HCC 接受原发性切除术的 1032 例患者的数据。其中87名患者（8.4%）服用了阿司匹林（阿司匹林组），945名患者（91.6%）未服用阿司匹林（非阿司匹林组）。采用倾向分数匹配法比较了配对队列中两组患者的短期疗效、无复发生存期（RFS）和总生存期（OS）：中位随访时间为 42.6 个月（95% 置信区间为 3.12-136.8 个月）。包括出血事件在内的短期结果无明显差异。在未配对的队列中，阿司匹林组肝脏切除术后的RFS和OS明显优于非阿司匹林组[5年RFS率：50.3% vs 31.4%，OS率：50.3% vs 31.4%]：5年RFS率：50.3% vs 31.4%，危险比（HR）0.55，P = 0.0002；5年OS率：82.9% vs 70.2%，危险比（HR）0.55，P = 0.0002：82.9% vs 70.2%，HR 0.46，P = 0.002]。在配对队列中，阿司匹林组肝脏切除术后的RFS和OS也明显优于非阿司匹林组（5年RFS率：50.3% vs 32.0%，P = 0.0002）：5年RFS率：50.3% vs 32.0%，HR 0.60，P = 0.003；5年OS率：82.9% vs 74.6%，HR 0.60，P = 0.003]：结论：使用阿司匹林能提高癌症患者的生存率（5 年 RFS：50.3% vs 32.0%，HR 0.60，P = 0.003）：结论：使用阿司匹林可改善接受原发性切除术的 HCC 患者的预后。
Prognostic impact of aspirin in patients with hepatocellular carcinoma after liver resection: propensity-score-matched analysis.
Background: The association between aspirin and hepatocellular carcinoma (HCC) has been reported to prevent carcinogenesis caused by hepatitis B or C virus infection. The objective of this study was to investigate the prognostic impact of aspirin in patients who underwent liver resection for HCC.
Methods: Data for 1032 patients who underwent primary resection for HCC between 2000 and 2019 were reviewed. There were 87 patients (8.4%) who took aspirin (aspirin group) and 945 (91.6%) who did not (non-aspirin group). Short-term outcomes, recurrence-free survival (RFS), and overall survival (OS) were compared between two groups in the matched cohort using propensity-score matching.
Results: The median patient follow-up was 42.6 months (95% confidence interval 3.12-136.8 months). There was no significant difference in short-term outcomes, including bleeding events. RFS and OS after liver resection in the aspirin group were significantly better than those in the non-aspirin group in the unmatched cohort [5-year RFS rate: 50.3% vs 31.4%, hazard ratio (HR) 0.55, P = 0.0002; 5-year OS rate: 82.9% vs 70.2%, HR 0.46, P = 0.002]. In the matched cohort, RFS and OS after liver resection in the aspirin group were also significantly better than those in the non-aspirin group (5-year RFS rate: 50.3% vs 32.0%, HR 0.60, P = 0.003; 5-year OS rate: 82.9% vs 74.6%, HR 0.56, P = 0.03).
Conclusion: Use of aspirin was associated with better prognosis for patients who underwent primary resection for HCC.
期刊介绍：
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
